South Korea · Delayed Price · Currency is KRW GL Pharm Tech Statistics
Total Valuation
GL Pharm Tech has a market cap or net worth of KRW 71.66 billion. The enterprise value is 89.13 billion.
| Market Cap | 71.66B |
| Enterprise Value | 89.13B |
Important Dates
The next estimated earnings date is Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GL Pharm Tech has 77.55 million shares outstanding. The number of shares has decreased by -6.53% in one year.
| Current Share Class | 77.55M |
| Shares Outstanding | 77.55M |
| Shares Change (YoY) | -6.53% |
| Shares Change (QoQ) | -22.50% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 54.46M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.94 |
| PB Ratio | 3.62 |
| P/TBV Ratio | 3.86 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 66.60, with an EV/FCF ratio of -15.18.
| EV / Earnings | -677.40 |
| EV / Sales | 2.42 |
| EV / EBITDA | 66.60 |
| EV / EBIT | 198.64 |
| EV / FCF | -15.18 |
Financial Position
The company has a current ratio of 0.95, with a Debt / Equity ratio of 1.04.
| Current Ratio | 0.95 |
| Quick Ratio | 0.47 |
| Debt / Equity | 1.04 |
| Debt / EBITDA | 19.37 |
| Debt / FCF | -3.51 |
| Interest Coverage | 0.28 |
Financial Efficiency
Return on equity (ROE) is -0.67% and return on invested capital (ROIC) is 0.48%.
| Return on Equity (ROE) | -0.67% |
| Return on Assets (ROA) | 0.23% |
| Return on Invested Capital (ROIC) | 0.48% |
| Return on Capital Employed (ROCE) | 0.67% |
| Weighted Average Cost of Capital (WACC) | 5.58% |
| Revenue Per Employee | 1.12B |
| Profits Per Employee | -3.99M |
| Employee Count | 33 |
| Asset Turnover | 0.78 |
| Inventory Turnover | 2.23 |
Taxes
In the past 12 months, GL Pharm Tech has paid 63.51 million in taxes.
| Income Tax | 63.51M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.04% in the last 52 weeks. The beta is 0.41, so GL Pharm Tech's price volatility has been lower than the market average.
| Beta (5Y) | 0.41 |
| 52-Week Price Change | -25.04% |
| 50-Day Moving Average | 1,026.86 |
| 200-Day Moving Average | 1,116.53 |
| Relative Strength Index (RSI) | 42.16 |
| Average Volume (20 Days) | 256,899 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GL Pharm Tech had revenue of KRW 36.86 billion and -131.58 million in losses. Loss per share was -1.81.
| Revenue | 36.86B |
| Gross Profit | 14.54B |
| Operating Income | 174.80M |
| Pretax Income | -68.07M |
| Net Income | -131.58M |
| EBITDA | 1.06B |
| EBIT | 174.80M |
| Loss Per Share | -1.81 |
Balance Sheet
The company has 3.15 billion in cash and 20.62 billion in debt, with a net cash position of -17.48 billion or -225.38 per share.
| Cash & Cash Equivalents | 3.15B |
| Total Debt | 20.62B |
| Net Cash | -17.48B |
| Net Cash Per Share | -225.38 |
| Equity (Book Value) | 19.80B |
| Book Value Per Share | 329.99 |
| Working Capital | -1.07B |
Cash Flow
In the last 12 months, operating cash flow was -2.73 billion and capital expenditures -3.14 billion, giving a free cash flow of -5.87 billion.
| Operating Cash Flow | -2.73B |
| Capital Expenditures | -3.14B |
| Depreciation & Amortization | 889.68M |
| Net Borrowing | 3.27B |
| Free Cash Flow | -5.87B |
| FCF Per Share | -75.71 |
Margins
Gross margin is 39.45%, with operating and profit margins of 0.47% and -0.36%.
| Gross Margin | 39.45% |
| Operating Margin | 0.47% |
| Pretax Margin | -0.18% |
| Profit Margin | -0.36% |
| EBITDA Margin | 2.89% |
| EBIT Margin | 0.47% |
| FCF Margin | n/a |
Dividends & Yields
GL Pharm Tech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 6.53% |
| Shareholder Yield | 6.53% |
| Earnings Yield | -0.18% |
| FCF Yield | -8.19% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GL Pharm Tech has an Altman Z-Score of 1.98 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.98 |
| Piotroski F-Score | 3 |